Editorial
doi: 10.1016/j.molmet.2021.101208.
Epub 2021 Mar 9.
Advances in the treatment of metabolic diseases
Affiliations
- PMID: 33729916
- PMCID: PMC8085582
- DOI: 10.1016/j.molmet.2021.101208
Item in Clipboard
Editorial
Advances in the treatment of metabolic diseases
Mol Metab.
2021 Apr.
No abstract available
Similar articles
-
Review: In type 2 diabetes, SGLT-2 inhibitors or GLP-1 agonists reduce mortality vs control or DPP-4 inhibitors.Ann Intern Med. 2018 Jul 17;169(2):JC2. doi: 10.7326/ACPJC-2018-169-2-002. Ann Intern Med. 2018. PMID: 30014091 No abstract available.
-
[Diabetes therapy--novel drugs to come (DPP-4 inhibitors, GLP-1 agonists, SGLT-2 inhibitors)].MMW Fortschr Med. 2010 May 20;152(20):43-4. doi: 10.1007/BF03366604. MMW Fortschr Med. 2010. PMID: 20552881 German. No abstract available.
-
[Novel indications for GLP-1-analogues and SGLT-2-inhibitors: when should a general practitioner prescribe these agents?].MMW Fortschr Med. 2021 Aug;163(14):57-61. doi: 10.1007/s15006-021-0085-3. MMW Fortschr Med. 2021. PMID: 34370254 Review. German. No abstract available.
-
SGLT-2 inhibitors were not linked to severe or nonsevere UTIs vs DPP-4 inhibitors or GLP-1 agonists.Ann Intern Med. 2019 Dec 17;171(12):JC70. doi: 10.7326/ACPJ201912170-070. Ann Intern Med. 2019. PMID: 31842228 No abstract available.
-
The cardiovascular safety trials of DPP-4 inhibitors, GLP-1 agonists, and SGLT2 inhibitors.Trends Cardiovasc Med. 2017 Apr;27(3):194-202. doi: 10.1016/j.tcm.2017.01.009. Epub 2017 Jan 28. Trends Cardiovasc Med. 2017. PMID: 28291655 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
